Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les actus Santé à ne pas manquer !

“We are honored that Infinio Ultra Sphere and Virto R Infinio have been recognized with the 2026 iF Design Award,” said Oliver Frank, Vice President Phonak Marketing. “This recognition reinforces our ...

Following the release, BioVersys will host a conference call and webcast on March 18, 2026 at 2:00 PM CET / 9:00 AM ET where management will review the financial results, provide a business update, ...

Purisaki Berberine Patches are transdermal supplement patches marketed as a plant-based formula for daily wellness and weight management support. The company describes them as an adhesive patch ...

An informational 2026 consumer evaluation examining common SugarHarmony search queries, ingredient transparency concerns, marketing claim context, refund and fulfillment policy requirements, and what ...

Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.

Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s ...

A live link to the presentation will be located under “ Events ” in the Investors section of the Company’s website at www.actuatetherapeutics.com. A replay of the webcast will be available on ...

DBV Technologies annonce sa participation à plusieurs conférences investisseurs en mars DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT – CUSIP : 23306J309) (la « ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced the company will participate at the following investor ...

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.

On September 2025, SCYNEXIS announced positive Phase 1 SAD/MAD results for the oral formulation of its second-generation fungerp, SCY-247, demonstrating good tolerability, favorable pharmacokinetics, ...